Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS® Growth and AUR200 Development

Download

• Small JPEG, 310x103, 16.9 KB
• Preview JPEG, 144x48, 11.1 KB
• Thumbnail JPEG, 120x40, 10.5 KB